Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. The company was founded in 1976 and is based in Minneapolis, Minnesota.
TECH Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for BIO-TECHNE Corp. To summarize, we found that BIO-TECHNE Corp ranked in the 14th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of BIO-TECHNE Corp, consider:
The company's balance sheet shows it gets 97% of its capital from equity, and 3% of its capital from debt. Notably, its equity weight is greater than 78.63% of US equities in the Healthcare sector yielding a positive free cash flow.
The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than merely 12.07% of the free cash flow producing stocks we're observing.
TECH's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 46.61% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of BIO-TECHNE Corp? See ZBH, BSX, QGEN, SIGA, and IDXX.
MINNEAPOLIS, Oct. 1, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Canadian office located in Toronto. This new office will be the workplace for approximately 40 Bio-Techne employees and reflects the Company's commitment to supporting the…
MINNEAPOLIS, Sept. 30, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the grand opening of its approximately 61,000 square foot state-of-the-art GMP (Good Manufacturing Practices) manufacturing facility. Located in St. Paul, MN, the new facility is dedicated to…
MINNEAPOLIS, Sept. 23, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy…
Bio-Techne (TECH) announces the commercial launch of new RNA-Protein Co-Detection Assays that enable visualization of single-molecule gene expression with single-cell resolution directly in intact cells and tissues.The company says the research-use-only tests allow researchers to simultaneously examine cell-type specific gene expression and identify cellular sources of secreted proteins....
MINNEAPOLIS, Sept. 22, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ technology with release of the new RNA-Protein Co-Detection Assays. The RNAscope technology is an advanced in situ…